Unigene Labs Adds CFO

David Moskowitz has been appointed chief financial officer at Unigene Laboratories, Inc. In this newly created position, Mr. Moskowitz will serve as a member of the company’s executive leadership team and lead the strategic direction of the company’s financial and capital markets activities.

Mr. Moskowitz spent the past 13 years as an equity research analyst covering large-cap pharmaceutical, specialty pharmaceutical, biotechnology, and generic drug companies. Most recently, Mr. Moskowitz served as a senior pharmaceutical analyst for Roth Capital Partners, LLC, where he developed research coverage of emerging specialty pharma and biotechnology companies.

Ashleigh Palmer, president and chief executive officer of Unigene, said, “We are extremely excited to welcome David to Unigene and look forward to benefiting from his in-depth knowledge of the pharmaceutical market space, strategic financial perspective, industry and Wall Street network, and strong credibility and reputation within the investment community. In executing Unigene’s turnaround strategy, we recognized the appointment of a chief financial officer would be a critical step in accelerating the next phase of our growth and addressing the priority challenge for Unigene in 2012, our substantial debt. I have no doubt whatsoever that David is the individual we have been searching for.”